ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$0.73 USD
-0.04 (-4.58%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.70 -0.03 (-4.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for ImmunoPrecise Antibodies Ltd falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -20.13 | -19.98 | -13.32 | -5.62 | NA |
Depreciation/Amortization & Depletion | 4.25 | 5.03 | 3.00 | 2.84 | NA |
Net Change from Assets/Liabilities | 1.76 | -2.46 | 0.46 | -0.78 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 10.98 | 2.50 | 1.94 | 3.09 | NA |
Net Cash From Operating Activities | -3.14 | -14.92 | -7.91 | -0.46 | NA |
Property & Equipment | -1.03 | -1.12 | -0.85 | -1.05 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -2.94 | 0.00 | NA |
Investments | 0.09 | 0.06 | 0.00 | 0.00 | NA |
Other Investing Activities | -0.21 | -0.42 | -0.36 | -0.83 | NA |
Net Cash from Investing Activities | -1.16 | -1.48 | -4.15 | -1.88 | NA |
Uses of Funds
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.75 | 0.54 | 3.07 | 33.78 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.13 | NA |
Increase (Decrease) Short-Term Debt | -0.99 | -1.01 | -0.77 | -0.72 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 0.76 | -0.47 | 2.30 | 33.19 | NA |
Effect of Exchange Rate Changes | -0.02 | 0.56 | 0.36 | -0.90 | NA |
Net Change In Cash & Equivalents | -3.57 | -16.31 | -9.40 | 29.95 | NA |
Cash at Beginning of Period | 6.20 | 22.61 | 33.35 | 2.06 | NA |
Cash at End of Period | 2.63 | 6.29 | 23.95 | 32.01 | NA |
Diluted Net EPS | -0.79 | -0.80 | -0.68 | -0.34 | NA |
Fiscal Year End for ImmunoPrecise Antibodies Ltd falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -20.13 | -6.76 | -4.56 | -2.67 |
Depreciation/Amortization & Depletion | NA | 4.25 | 3.08 | 2.10 | 1.12 |
Net Change from Assets/Liabilities | NA | 1.76 | 1.88 | 1.21 | 0.48 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 10.98 | 0.61 | 0.56 | 0.54 |
Net Cash From Operating Activities | NA | -3.14 | -1.19 | -0.69 | -0.53 |
Property & Equipment | NA | -1.03 | -0.20 | -0.32 | -0.10 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.09 | 0.09 | 0.09 | 0.06 |
Other Investing Activities | NA | -0.21 | -0.22 | -0.14 | -0.11 |
Net Cash from Investing Activities | NA | -1.16 | -0.33 | -0.37 | -0.15 |
Uses of Funds
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.75 | 0.69 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -0.99 | -0.77 | -0.53 | -0.30 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.76 | -0.08 | -0.53 | -0.30 |
Effect of Exchange Rate Changes | NA | -0.02 | 0.06 | -0.07 | -0.19 |
Net Change In Cash & Equivalents | NA | -3.57 | -1.54 | -1.67 | -1.16 |
Cash at Beginning of Period | NA | 6.20 | 6.19 | 6.16 | 6.27 |
Cash at End of Period | NA | 2.63 | 4.65 | 4.49 | 5.10 |
Diluted Net EPS | NA | -0.53 | -0.08 | -0.07 | -0.10 |